MAVEN PHARMACY LIMITEDActive

Company number 12972946Private limited companyIncorporated 2020

Key figures

£529,107+48.8%
Net assets 2024/25
-200 k0200 k400 k600 k2020/212021/222022/232023/242024/25

Like most small UK companies, MAVEN PHARMACY LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m1.5 m2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand2,4151,25739922,791—
Total assets208,31240,2091,328,6411,356,2831,388,696
Total liabilities1,051,804731,4331,078,1521,000,768541,309
Net assets / total equity-16,73099,083250,489355,515529,107
Average number of employees22200

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: MAVEN PHARMACY LIMITED

Company

MAVEN PHARMACY LIMITED is a private limited company registered with Companies House under company number 12972946. It was incorporated on 26 Oct 2020. Its status is active. The registered office is in Tipton (DY4). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460), dispensing chemist in specialised stores (47730), buying and selling of own real estate (68100), other human health activities (86900).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Oct 2025); the company files micro-entity accounts. Net assets were £529,107, up 48.8% on the previous year. Total assets were £1,388,696 and total liabilities £541,309. The company had an average of 0 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

2 persons with significant control are registered. 3 of 7 registered charges are outstanding.

Filing deadlines

The next accounts are due by 31 Jul 2027. The next confirmation statement is due by 8 Nov 2026.